These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 34166770)
21. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756 [TBL] [Abstract][Full Text] [Related]
22. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901 [TBL] [Abstract][Full Text] [Related]
23. Potential Therapeutic Strategies for Targeting Y-Box-Binding Protein 1 in Cancers. Yang JW; Sun C; Jin QY; Qiao XH; Guo XL Curr Cancer Drug Targets; 2021; 21(11):897-906. PubMed ID: 34465278 [TBL] [Abstract][Full Text] [Related]
24. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Bader AG; Vogt PK Oncogene; 2008 Feb; 27(8):1179-82. PubMed ID: 17704806 [TBL] [Abstract][Full Text] [Related]
25. YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention. Davies AH; Dunn SE Oncotarget; 2011 May; 2(5):401-6. PubMed ID: 21576761 [TBL] [Abstract][Full Text] [Related]
26. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. Liao LZ; Chen CT; Li NC; Lin LC; Huang BS; Chang YH; Chow LP Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379356 [TBL] [Abstract][Full Text] [Related]
27. A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Alkrekshi A; Wang W; Rana PS; Markovic V; Sossey-Alaoui K Cell Signal; 2021 Sep; 85():110073. PubMed ID: 34224843 [TBL] [Abstract][Full Text] [Related]
28. Y-box-binding protein 1 (YB-1) and its functions. Eliseeva IA; Kim ER; Guryanov SG; Ovchinnikov LP; Lyabin DN Biochemistry (Mosc); 2011 Dec; 76(13):1402-33. PubMed ID: 22339596 [TBL] [Abstract][Full Text] [Related]
29. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753 [TBL] [Abstract][Full Text] [Related]
30. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Bader AG; Felts KA; Jiang N; Chang HW; Vogt PK Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12384-9. PubMed ID: 14530393 [TBL] [Abstract][Full Text] [Related]
31. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491 [TBL] [Abstract][Full Text] [Related]
32. YB-1 Phosphorylation at Serine 209 Inhibits Its Nuclear Translocation. Sogorina EM; Kim ER; Sorokin AV; Lyabin DN; Ovchinnikov LP; Mordovkina DA; Eliseeva IA Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008856 [TBL] [Abstract][Full Text] [Related]
34. Targeting AKT/PKB to improve treatment outcomes for solid tumors. Iida M; Harari PM; Wheeler DL; Toulany M Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136 [TBL] [Abstract][Full Text] [Related]
35. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Basaki Y; Hosoi F; Oda Y; Fotovati A; Maruyama Y; Oie S; Ono M; Izumi H; Kohno K; Sakai K; Shimoyama T; Nishio K; Kuwano M Oncogene; 2007 Apr; 26(19):2736-46. PubMed ID: 17072343 [TBL] [Abstract][Full Text] [Related]
36. Crystal structure of a Y-box binding protein 1 (YB-1)-RNA complex reveals key features and residues interacting with RNA. Yang XJ; Zhu H; Mu SR; Wei WJ; Yuan X; Wang M; Liu Y; Hui J; Huang Y J Biol Chem; 2019 Jul; 294(28):10998-11010. PubMed ID: 31160337 [TBL] [Abstract][Full Text] [Related]
37. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Sutherland BW; Kucab J; Wu J; Lee C; Cheang MC; Yorida E; Turbin D; Dedhar S; Nelson C; Pollak M; Leighton Grimes H; Miller K; Badve S; Huntsman D; Blake-Gilks C; Chen M; Pallen CJ; Dunn SE Oncogene; 2005 Jun; 24(26):4281-92. PubMed ID: 15806160 [TBL] [Abstract][Full Text] [Related]
38. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. Maier E; Attenberger F; Tiwari A; Lettau K; Rebholz S; Fehrenbacher B; Schaller M; Gani C; Toulany M Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31010234 [TBL] [Abstract][Full Text] [Related]
39. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity. Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462 [TBL] [Abstract][Full Text] [Related]
40. Mechanism of YB-1-mediated translational induction of GluR2 mRNA in response to neural activity through nAChR. Tanaka T; Ohashi S; Moue M; Kobayashi S Biochim Biophys Acta; 2012 Jul; 1820(7):1035-42. PubMed ID: 22526143 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]